This integrative approach provides insights into breast cancer biology and highlights C. urens as a promising candidate for developing targeted treatments, especially for the HR+/HER2-subtype, potentially enhancing therapeutic outcomes in challenging cancer cases. This evidence concerns the gene HR and cancer.